Merck & Company Inc (MRK)vsRevvity Inc. (RVTY)
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
RVTY
Revvity Inc.
$99.09
+7.36%
HEALTHCARE · Cap: $9.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2203% more annual revenue ($65.77B vs $2.86B). MRK leads profitability with a 13.6% profit margin vs 8.4%. RVTY appears more attractively valued with a PEG of 0.53. RVTY earns a higher WallStSmart Score of 63/100 (C+).
MRK
Buy53
out of 100
Grade: C-
RVTY
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Margin of Safety
+7.8%
Fair Value
$109.59
Current Price
$99.09
$10.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.1%
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
ROE of 3.2% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : RVTY
The primary concerns for RVTY are Return on Equity, P/E Ratio. A P/E of 42.1x leaves little room for execution misses.
Key Dynamics to Monitor
RVTY carries more volatility with a beta of 1.13 — expect wider price swings.
RVTY is growing revenue faster at 5.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVTY scores higher overall (63/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?